Q2 2023 Lucid Diagnostics Inc Earnings Call

Speaker 1: Good day and welcome to the Lucid Diagnostics 2nd Quarter 2023 Business Update Conference call.

Speaker 2: The drivers of this growth were increased solar productivity and continuing increased activities through our satellite use at test centers and our high-volume testing events. We also had some very important strategic accomplishments in the last quarter and in recent weeks that really bode well for us in the coming quarters. A very important milestone was that we upgraded our revenue cycle management infrastructure and provider. That was a process that took all of May and most of June , and that process is now completed. Again, I'll talk about that in some more detail. And we've certainly saw an immediate positive impact on our claims processing and payments, which Dennis and I will both review in some detail during the month of July .

Speaker 2: The prospective clinical utility studies that we've been talking about each quarter and are very critical for our engagement with payers reached its first enrollment milestone. It actually surpassed it at over 500 patients between the two studies, and those results will be—are being analyzed. They'll be posted, and the first manuscripts will be submitted later this month. We also were excited to see the unprecedented results from the end of the year.

Speaker 2: a company will be offering Esogard as an employee benefit. So again, we'll talk about those in a bit more detail. A few slides just to introduce those of you who are new to the story. Lucid has two key products, Esogard and EsoCheck. The Esogard molecular diagnostic test, or EsoCheck esophageal DNA test, and the EsoCheck cell collection device. They form the first and only commercially available test that's capable of serving as a widespread tool.

Speaker 2: to prevent cancer deaths through early detection of esophageal pre-cancer. Both of the major gastroenterology associations have supported non-endoscopic biomarker testing, which ours is the only one that's commercially available as an acceptable alternative to endoscopy. Next slide. The enemy is esophageal cancer.

Speaker 2: is considered an opportunity for a cure. Therefore, the only way to actually have an impact on deaths is to detect the pre-cancer, and that's just not happening. Less than 5% of those recommended for screening by guidelines are undergoing endoscopy. I thought today I'd share a patient story, because at the end of the day, this is about patients and saving lives and are using early detection to save lives. And I did touch on this during a testimony on Capitol Hill last month, but I thought I'd really tell a bit more of the story here to give you a sense as to how every day the work that our team does is driven by the opportunity to have an impact on patients' lives, such as this patient who we'll call Steve.

Speaker 2: Steve's a 70 year old white male former smoker lived in the Pacific Northwest Had long time suffer of chronic heartburn. He was on PPI medications such as Prilosec And he'd had an endoscopy over 20 years ago, but no follow-up since then He was in his allergist waiting room and he met Freddy Freddy food to you over the right So one of our educational posters that Freddy saying check your food

Speaker 2: The poster had some criteria on it as to who should be considered, and he could have in his head checked through the boxes and realized he had heartburn. He was over.

Speaker 2: He asked the physician allergist to order the test. And they did. The cell collection procedure was performed at that physician office, this is one of those offices where the personnel are doing the Easter check procedure themselves. And the test came back positive. He had a follow up in DOSCOB, as all patients who have a positive EasterGuy test are recommended to undergo. And the DOSCOB show that he had a two-witch patch, which is quite a long segment.

Speaker 2: as these things go, and it showed a late stage precancer, so-called high grade dysplasia. This is the last step before developing this highly lethal cancer, and it was picked up only because he was thought about his health, read the poster, and was assertive about his health, and asked for the test.

Speaker 2: I think we can unequivocally say that if he had not undergone the test, that sometime in the coming years, that it's very likely that his dysplasia would have progressed, or that the precursor would have progressed again.

Speaker 2: So he underwent what patients with this diagnosis are recommended to undergo, which is he was referred out of state and underwent a series of curative ablation procedures that are done using endoscopy and that was completed last month. And I think really I can't say it any better than he did, and this is a direct quote, he said, I think I saved my own life by seeing the flyer and getting the test.

Speaker 2: I'm damn lucky that I caught it. When I caught it, the more prevention, the easier the cure. So that really says it all. From a commercial point of view, the opportunity here is vast. We know the number of patients, this 30 million patient population is really the core group of those who have chronic heartburn and patients who are recommended for pre-cancer testing by guidelines. Some of the guidelines have actually expanded that number beyond that.

Speaker 2: Medicare has set a price of $1,938, and as we've said on prior calls, that price does appear to be holding as we grow our activity and increase our...

Speaker 2: engagement with payers. So that's a very, very large market opportunity and we have a very high gross margin of over 90% at volumes that are close to where we are today.

Speaker 2: So how did we do in this past quarter from a commercial point of view? As I mentioned, be regarded.

Speaker 2: We took our testing volume group 20%, quarter on quarter, to 2200 tests. And you can see we've had just very nice, steady, double digit growth for a period of time, going back about six quarters. I did want to note, because we get asked this a fair amount, as we're growing test volume, are we approaching capacity with regard to our laboratory or manufacturing? And that is, we are not. We have, our laboratory's able to perform over 10,000 tests per quarter, and we have sufficient manufacturing.

Speaker 2: and where is the subcollection portion of the test being performed. We've stabilized about 50 to 60% of the patients are being referred by primary care physicians and the rest are being referred by a variety of specialists and institutions. One thing that is changing is we continue to show increased risk of COVID-19.

Speaker 2: in the number of patients that are being performed, where the cell collection procedure is being performed by our nurse practitioners. And an increasing number of those are being performed at the satellite lucid test center. So the physical lucid test centers are the centers we have in 13.

Speaker 2: cities across the country, but we all we have nurse practitioners who are based there, that's their anchor, that's their home, but they are able with the satellite test centers to branch out and travel to physician offices and hold sessions there where they spend the day doing the cell collection procedure in the physician office. And we still have about a third of the time patients are undergoing the test by their own physician as Steve did with his allergist.

Speaker 2: Next slide. So really great views on the commercial execution. Really proud at how the test volume.

Speaker 2: is growing. If you note that earlier in the year, at the beginning of the year, we actually froze our sales team. And that field team, which consists of both the sales representatives, sellers, as well as the clinical team, the nurse practitioners have shown increased productivity since the beginning of the year. So same number of sellers are generating this growth. There's improved coordination between the sales and clinical team. Some of that's driven by these high volume testing events, which put a demand on our system. And the nurse practitioners, the folks who do the ESEQS on collection procedure, continue to hit it out of the park with a 99% technical success rate and very high sufficient DNA rates. As I mentioned, the satellite lucid test center.

Speaker 2: multiple patients scheduled and it helps with physician engagement. It keeps the testing front and center. So that continues to be the case quarter on quarter. We continue to see that positive impact. We launched our first mobile test unit in Florida. Florida is a state where the regulatory requirements required us to do that in order to have a

Speaker 2: satellite model and the demand for that is strong. Practices want us to bring them into their parking lot where patients are tested, we get walk-ins where patients ask for the test and have the physician or their team order on the time. And it's also not a bad marketing tool to have our van with Freddie and the marketing message driving around Florida. We've been asked about expanding that and moving that in other states and that's something we're considering but for now we're continuing to drive this volume here. In other states we don't have that mandatory need to have a mobile test unit so we'll continue to push forward as we're doing. We announced the Check Your Food Tube pre-cancer detection event. This was started in the first quarter of this year. With firefighters, the growth in those activities continue. We continue to do many of these, some smaller, some larger. They continue to represent a significant portion of our community.

Speaker 2: from volume, but importantly, again, people do inquire about this. That growth is not cannibalizing the growth in the traditional referral business from primary care physicians and other specialists. So it's additive, it's part of our philosophy of looking at every opportunity to increase access, patient access, wherever it might be. We've moved from, although they've been mostly firefighters, we've had police departments do this, and we're continuing to expand that reach. Again, also, it expands our geographic reach, get strong media exposure. There have been many examples where we've had a CYFT event, and then physicians, including one major, um, um,

Speaker 2: The hospital center contacted us after hearing about a firefighter event in their region and led us to increase our activity there and divert resources there. All of this is complicated. It takes time and some effort to get these organized and we have a dedicated program manager that's been installed and enhanced.

Speaker 2: the operational efficiencies substantially. So this will remain a significant part of our effort to get patients access to this type of treatment.

Speaker 2: And we've also had an increased focus on large health systems and IDNs. These are more difficult. They take more time. There's a little more lead time, but obviously the payoff can be large if you can get a large regional or even national health system in play. We've made progress in getting through technology clearance committees and so forth and working to translate those early successes into...

Speaker 2: into more systematic activity within a strategic account. So we have a large pipeline of accounts that we've engaged with and we're looking towards locking those down in the coming quarters.

Speaker 2: So a few comments about claims, payment, and coverage. These are topics that Dennis will talk about in some detail. I just wanted to highlight a few of the strategic aspects of this. If you look at the graphic on the right there, I just want to remind you that there are multiple things that go towards our ability to collect payment for the tattoo.

Speaker 2: for the tests that we perform to get longer term contracts that provide us coverage and ultimately to drive revenue growth.

Speaker 2: They include generating a claims history. You won't get paid by commercial payers until they see your test being ordered and claims being submitted and even passing through the process of appeals and so forth.

Speaker 2: It's dependent on having a robust revenue cycle management process. It's dependent on generating clinical utility data, which I'll talk about in a bit more detail later, but it's a very, very critical part of our engagement with payers. The vast majority of time their primary questions are around have you demonstrated clinical utility. We'd like to see that. And then there's a whole discipline around market access and engaging on medical policy, and all of that is another important driver. So we've made substantial progress on all of them. The most important one.

Speaker 2: for the near term is the upgrade we've made in our revenue cycle management infrastructure. We previewed this, was about to happen on our last call and that process has now been completed. We engaged the market leader in diagnostics RCM. This is a company that has a significantly larger capacity than we had and in fact was the, for many years, was the RCM provider for one of the largest multi-billion dollar molecular diagnostic companies. We, in order to facilitate the transition, we.

Speaker 2: paused claims submissions and adjudication for about a six-week period from the beginning of May to June 12th that had a near-term, short-term impact on claims and receipts from that. But the immediate positive impact in July was really striking to all of us. That impact was positive on all fronts, including the fact that the COVID-19 pandemic has been a major impact on the health and safety of our children. And so, we're really looking at the impact

Speaker 2: the average allowed success at allowed.

Speaker 2: payments as well as the net average sale price. Again Dennis will go through some of those numbers as a bit of a preview. These were obviously in this quarter not in the prior quarter.

Speaker 2: The another key element to being successful with the commercial payers is the appeals and prior authorization processes These can be quite They're very important You actually have to go through appeals to get in front of medical directors to get medical necessity and other aspects of their coverage decisions

Speaker 2: to engage with them on that. That process is much more robust than it was six weeks ago and we're very happy with our new partner in that regard. As I mentioned again, I'll reiterate that the drivers of payment coverage and revenue growth are still claims history in clinical utility. We've also revamped our market access and medical policy team. We have a new strategically focused leader in this role that started yesterday.

Speaker 2: And we're looking forward to a whole variety of initiatives and engagements with payers that she will lead us to. A brief comment here on our direct contracting strategic initiative. Again, we've touched on this before. This is an effort for us to go directly to employers, unions, other

Speaker 2: self-insured entities and seek to directly contract for Easter guard services with them. That process is more fruit. We have our first employer contract with the Texas-based automotive group. We'll be providing more information on that in the coming weeks.

Speaker 2: quite aggressively and we actually are hiring someone to be a director in this role. Okay, I've already mentioned clinical utility. Let me mention it again because this is really at the heart of our efforts to engage with our commercial payers, with payers, and in order to drive network and network coverage. Clinical utility means that our test has an impact on medical decision making. What a payer wants to know is that if our test is positive, that that will result in a follow up test, a follow up endoscopy to demonstrate that, to confirm the diagnosis and generate a follow up plan, either surveillance, ablation, or some other treatment.

Speaker 2: They also want to know that if a test is negative, that the patient will more than likely not get another expensive test like an endoscopy. So that fork in the road is actually very straightforward for our test, it's actually more complicated than some other diagnostic tests. It's quite straightforward and it's really the algorithm I just mentioned. The key type of data that the payers are looking for is prospective data. And so as we've discussed before, we have two studies, the CLU study, which is a prospective multi-center study.

Speaker 2: We have a total of over 500 patients between the two.

Speaker 2: That is sufficient for us to analyze the data, submit it for, post it on a preprint server and submit it for peer review by the end of this month.

Speaker 2: And we look forward to doing that. That is the process by which we'll be able to highlight that data for payers and engaging in coverage discussions, demonstrations of medical necessity, and negotiations for in-network contracting. So that process is ready to go. We're going to have our first set of data, and we're going to be able to present that to payers in the very near future. We also have the retrospective analysis from the very first high-volume testing event on the San Antonio firefighters. That's retrospective, so it's not as powerful, but it is useful. The data on that was excellent. I think that's a great example of the percentage of data

very, very high concordance with the outcome of the test and the appropriate medical decision being made for the test as I described previously. That manuscript was submitted and it's undergoing peer review in a gastroenterology journal. Another useful type of test that is commonly used in these kinds of discussions with payers are virtual patient studies, where you recruit physicians to give their decision as to what they would do in a very structured vignette fashion. That is a study of ongoing recruitment and we're looking forward to closing that in the near future.

future as well, so that'll be a nice supplemental piece of data, but the central data will be from the clue study in the registry. That's clinical utility. I won't be talking in much depth about the clinical validity studies. Those are studies that just continue to document the performance of our assay, of our tests, as was published originally in Science Translational Medicine years ago. So there are...

Five studies, the BetterNet study, the VA study, which we've previously announced, the BE1 study, which is a study that we enrolled about 150 patients in before pausing. That data is being analyzed. The BE2 study is another case control study that we're continuing to enroll into and will likely have a readout in the first half of next year. And Case Western Reserve also has a non-GERT study that's ongoing.

in its enrollment. I won't talk on the details of those except for a brief highlight of the Betanet results from the NCI. I'm just going to give a brief summary of that. We plan on providing more information on that in a couple of weeks.

well.

So the betternet study.

The BetterNet is a consortium of major academic medical centers. They're really the leading figures in esophageal disease and esophageal pre-cancer. You can see venerated names on the right there. Case Western, Mayo Clinic, Hopkins, Wash U, UNC, and Cleveland Clinic all participated in this study. It was a case control study of endoscopy versus our E-Sugart test. This is the first study that used real-world use of the test and with our standard room temperature preservative. The previous study was more of a research study in frozen samples. So that was a very important milestone for us to achieve. 100% of the patients in this study underwent ESO-Check cell collection. Again, that wasn't true in the original Science Translational Medicine paper. You can see the numbers there. I won't go through the full breakdown of the patients, but they started with about 365 patients and had at the end 242 that were valuable. I will highlight two numbers on that, the 83% Technic success rate and the 72% overall success rate. Just to note that these results, which are excellent, but I'll show on the next slide.

occurred despite the fact that the overall success rates were lower than we would like. These were centers that were doing this a bit earlier in our experience and centers that did not have the same rigorous competency training that we have now for academic centers but predominantly for our own nurse practitioners. So I highlighted earlier that our in-house elusive test center technical success rate is 99%, which is substantially better than the 83% here, and our overall success is about 95% again, substantially better than 72%. So we believe that the excellent results that are reported here are likely to be better given the current benchmark for the overall success. So one last slide here which has the results, the headline results from this test, and I'll caveat before I go into some detail but we are...

showing some other comparable early cancer detection tests as targets. These are not head-to-head comparisons. What I'd like to show here is what other highly successful or expected to be successful early cancer detection tests, the metrics that were used, the performance metrics that were used, that led to them being approved, FDA approved, getting coverage, and being, while it being, certainly in Collegrard's case, wildly successful. Many of those were...

screening studies and their intended use population, the E-Sugard results are a case control study. That said, E-Sugard picked up 100% of the cancer.

which is as you can see there, obviously Cologuard does quite well in that regard. The GARDEN, which is the liquid biopsy blood test that's getting a lot of attention, is at 83% and in stage one those numbers are quite poor at 55%, all of the 100%

cancers that were detected by Isigart were stage one cancers. The greater picture is on the pre-cancer side. The 81% detection rate for pre-cancer is really unprecedented for a molecular diagnostic test.

Cologuard picks up advanced added numbers at about a 42% clip. That number's a bit better in our most recent study. The blood tests for cancer hardly do at all, 13% for GARDEN. So this 82%, this 81% number, and then the overall 85% number, which is dominated by the precancers.

is really, again, quite unprecedented and critical for this cancer. Picking up a stage one colon cancer, as I mentioned, has an opportunity for a cure. We have to. We have no choice but to have the cancer detection rate in the 80% range, and we're gratified that that number is holding. There's some additional numbers on the right. I won't go through all three of them, but the negative predictive value is a good gut check. That's an estimated number based on what we expect the prevalence to be. That's at 99%, and that's where it needs to be.

Again, very comparable, if not better than what the benchmark is for others.

So with that I will hand the baton over to Dennis and we'll get a summary of our financial results.

hand the baton over to Dennis and we'll get a summary of our financial results. Thanks, Bijan.

the summary financial results for the second quarter and the first half of the year we'll report our press release that was published last night.

On these next three slides, I'll emphasize a few key highlights from the quarter, but I encourage you to consider those remarks in the context of the full disclosures covered in our quarterly report from Form 10-2. It was filed with the SEC last night and is available on our website. So on slide 16 here is our balance sheet. Cash, 32.6 million, reflects a sequential burn rate of 6.9 million.

The burn rate in the first quarter was about the same at 6.6 million. Obviously the simple math suggests that if this rate is sustained it puts our runway for more than a year.

The burn rate is softened by PathMed currently deferring payment of the quarterly management services agreement.

which creates optionality for paying the outstanding inner company obligation in stock or cash.

creates optionality for paying the outstanding inner company obligation in stock or cash, which is at Padme's future election.

Furthermore, as cash collections continue to accelerate, as we'll talk about in a second.

This can further throttle the burn rate for the upcoming quarters.

Then their payables were flat for the sequential quarter as was also the case in the first quarter. So the burn rate is not substantially influenced by changes in key net working capital balances.

The intercompany debt to Padme increased by $3.1 million, for which $2.3 million is the quarterly shared services charges.

The shares outstanding including unvested restricted stock awards as of today is 43.7 million shares, which is substantially unchanged from the first quarter.

The GAAP outstanding shares are reflected on the slide as well as the face of the balance sheet in the 10Q.

outstanding shares are reflected on the slide as well as the face of the balance sheet in the 10Q. On the next slide, slide 17.

compares this year's second quarter to last year's second quarter, and similarly for the six-month totals on certain key items.

Trustee will review the information in my comments in light of the cautionary disclosure in the bottom of the slide about supplemental information, particularly non-GAAP information. I'm required to say that. Revenue for the second quarter reflects actual cash collections for the quarter, plus invoiced ESOGUARD tests to the VA. With regard to the prior year, you will recall there was a fixed monthly fee received from the third-party lab that we used before setting up our own lab, and that agreement terminated in February of 2022.

You will recall from our discussion on the last quarterly call and the comments that we made a major change and upgrade to our revenue cycle management.

to allow Quad-X to come on board, which they did in mid-June, and more effectively handled processing and reporting on the claims we had in hand. And I'll give you some statistics at the end here. So far, in the short period of time, just since the beginning of the third quarter, collections for third-party reimbursement claims have tripled what was collected in the entire previous quarter. As a reminder, revenue recognition. A key determinant is the probability of collection. And therefore, due to the fact that we are in the early stages of our reimbursement process, this means revenue recognition occurs when the claim is actually collected.

First when the patient report is invoiced and submitted for reimbursement. As you'll see in our 10-Q this is called variable consideration in the jargon of GAP's ASC 606 revenue recognition guidelines.

and presently there is insufficient predictive data to reflect revenue when the test report is delivered to the referring physician. However, Quad-X is developing that database for us to eventually change from cash collection recognition to when the service is delivered.

Our non-gap loss for the second quarter of 9.6 million reflects a 2.4% sequential decrease.

for the second quarter of 9.6 million reflects a 2.4% sequential decrease compared to the first quarter loss.

and approximately a 10% decrease from the fourth quarter of last year as a result of the cost control initiatives we put in place at the beginning of the year. The next slide, slide 18, is a graphic illustration of our operating expenses for the periods reflected. Total non-GAAP OpEx of $9.7 million for the second quarter of 2013 reflects a sequential decrease in data quality.

of 11.3%. However, in our last quarterly call, we mentioned that in the first quarter, there were approximately 1.2 million of certain one-time expenses as we rationalized our base level expenses. Taking into account these measures, the normalized OpEx levels for both first quarter and second quarter are about even with each other. And both reflect a 9% decrease from the fourth quarter of last year, again as a result of the cost controls we put in place at the beginning of the year.

However, in our last quarterly call, we mentioned that in the first quarter, there were approximately 1.2 million of certain one-time expenses as we rationalized our base level expenses. Taking into account these measures, the normalized OpEx levels for both first quarter and second quarter are about even with each other. And both reflect a 9% decrease from the fourth quarter of last year, again as a result of the cost controls we put in place at the beginning of the year. Except for cost of revenue.

per share, reflecting a 4.9 million decrease in our sequential net loss. Contributing to this 4.9 million improvement, about one half came from financing related activities in the first quarter and the remainder was a general reduction in OPACs, mainly stock based comp and other non-cash charges. Now as promised, some statistics in the market access. First, the split between commercial

reflecting a 4.9 million decrease in our sequential net loss. Contributing to this 4.9 million improvement, about one-half came from financing-related activities in the first quarter, and the remainder was a general reduction in OPACs, mainly stock-based comp and other non-cash charges. Now, I promised some statistics in the market access. First, the split between commercial and Medicare, Medicaid.

was in the past about 92, 8%, 8% Medicare and Medicaid. It's not significantly higher, it's about 82, 17% split, so a little bit higher on the Medicare and Medicaid, but that's substantially changed. Since Quad-X took over, an indication of some of the statistics that they provide us, so we continue to monitor the performance.

They submitted just over 2,000 claims, 2,100 claims. Of those, less than half, 943 have been adjudicated. This is a term we're gonna use a lot going forward. Out of the claims that were adjudicated, a decision or an allowance of an amount to be paid with 349 claims, 37%. Importantly, the amount that was allowed when those claims that were adjudicated and determined to be allowed has increased from past quarters, it presently is just under $1,890.

This represents the insurance company's payment rate. It does not take into account an individual patient's deductible or copay. It's the allowance. But it's an indication that they are resetting the payment rate at the Medicare level. And this is in effect

A lot of payments are considered out of network, but we're going to focus on allowance going forward because we think that levels the playing field from quarter to quarter to determine progress being made on the insurance level.

So, with that, operator, let's open it up for questions. We will now begin the question and answer session.

To ask a question, you may press star then 1 on your touch tone phone. If you are using a speakerphone, please pick up your handset before pressing the keys. If at any time your question has been addressed and you would like to withdraw your question, please press star then 2.

At this time we will pause momentarily to assemble our roster.

The first question today comes from Kyle Meikman with Canaccord. Please go ahead. Hey, Kyle. How are you? Hey, guys. How are you doing? Thanks for taking the questions. All right. So, good. Congrats on the volume. Nice to see the solid increase sequentially. And I think I understand what happened here with the RCM provider and the switch here. And it sounds good in July going forward. Can you possibly see the difference between the two? Yes, sir. Can you see the difference between the two? Yes, sir. Can you see the difference between the two? Yes, sir.

Yeah, Quad-X just picked up all of those, we actually suspended those claims and waited for Quad-X to be online and they reached back to that date. That's why the statistic I just gave from May 1st to August 14th represents the claims that they submitted, some of which were from May to June 30th.

and then the balance since that time. And that total in that period of time was a little over 2,000. So, stopped submitting May 1st, and that got picked up in June 12th, and they submitted all of the backlog. So, just to use your term, no claims were lost, and no test volume was lost obviously.

that resulted in timing of collections, but not in loss tests. Right, I should have said shifted to the second half of the year, but I heard your stat at the end there Dennis, I was just confirming if that was what you were talking about, but that's perfect, that's great. Yes, correct. In terms of the high-volume testing impact in the quarter, maybe just walk through that and maybe talk about how we were thinking about that going forward, if it's recurring and organic revenue growth source, or is it still just upside and we shouldn't really expect money that was happening going forward? I think it's upside, but it's also a key part of our growth. So in the first quarter, the first quarter total had about 450 tests from those high-volume events, check your Food Tube events, and it was slightly higher in the second quarter, about an 8 or 9% growth. So to get to your question, your organic growth.

of non-test events was around 23% for an overall blend of 20%. Yeah, and that's consistent with the strategy problem, right? We've said this before, I'll say it again, that we're not shifting from one strategy to another. This is all the above strategy. Any opportunity we have to get patients access, we're seeking them. And these high-volume events are a very, very productive tool for us. It's a different modality. It's typically one physician where we find a physician champion.

We find a group, as I said, we started with firefighters, but we're diversified beyond that. And we find a real interest and need and demand for doing these tests, and we can do them in a very efficient way because our nurse practitioners can...

can do 30 of these per MP per day. So it'll remain an important role. We've really fine-tuned our comp plans to make sure that we're not cannibalizing one for the other, so there's still the same incentive to drive the individual sort of boots on the ground, physician-driven referrals. And we expect to see growth in both. Okay, awesome, thanks so much, guys. And Lisa, I want for you on the prior authorization process. Well, eSUGAR is such a novel kind of diagnostic and an ESUGAR check as well. The procedure itself, pretty new. It's been on the market for like two or three years.

Well it's multifaceted as you know these are the whole commercial payer process is very can be complex it could be very diverse with regard to how people engage. I'll just put at the top that for the larger sort of you know the kind of the big in-network contract the home run so to speak that is

The commentary is almost always about clinical utility, you know, come back to us when you have sufficient clinical utility. But that's not to say that, you know, as Dennis said, we're actually with an upgraded provider that's helping us engage with payers on a claim-by-claim basis. Many of those interactions are, like you said, they involve, even if they get denied initially, there's an appeal, and the appeal often is that we see the

engagements the volume has gone up and more more more interaction with medical directors and you know there's certainly been great progress over the last six weeks in terms of how those conversations are going and the proportion of the that are resulting in a lab claim so early still early but they really does bode well quite excited for the coming quarters. The tax has a very sophisticated appeals process.

One is medically not necessary which is

that boggles our mind given the guidelines that are out there to establish that. And the other is... But often those are just like interrupt. Those are often just the label that had an administrative person's lapsed down and that's an opportunity to have a conversation with a medical director to actually make the case that it is medical. And that's where the appeal process comes in. And ultimately that'll be cured by a network coverage. And then the second is it's non-covered routine screening exam, which again is incomprehensible given the...

the history and the guidelines and the risk factors these patients have to demonstrate before they can get tested. So that'll change in time. Perfect. Just one more before I hop off. The Lucid registry and the Multisensory Clue studies, what is the expected timing for the peer-reviewed publication for that? Like, do you think that that would be published within, like, a year from now?

Oh certainly within a year yeah but I but I but I yeah thanks for giving me a broad raise here because the peer review can be a little bit hard to predict right we are committed to this has become common practice now we are committed to as soon as we have the manuscript complete of the data fully scrubbed

to post it on a preprint server while the peer review process is going on. And so that actually does provide us with an actual manuscript that we can initiate conversations in. So it's a little bit hard to say. Clinical utility studies are not often like, I guess, a traditional...

clinical studies, so a little bit hard to know how long it will take to get it to clear peer review. But we'll have plenty of opportunity during the peer review process to use the preprint manuscript to engage in conversations with peers.

Great, thanks, Deshaun. Thanks, Dennis. The next question comes from Mike Matson with Nita Minkow. Please go ahead. Good morning, just one on, you know, just with the new...

revenue cycle management process or partner, I guess. You know, how long do you think it's going to take until you can shift from your billing on collections to – sorry, hum.

recording revenue, recognizing revenue on collections to submissions I guess of claims and

That's hard to determine, Mike. I know from other companies that process could be anywhere from six months to two years and it really depends upon where we, the speed of which things change from out of network to in network and contracts and being paid by contract. It all comes down to the predictability of when we submit a claim to a third party.

the likelihood of getting that amount paid and adding some degree of intelligence to that based upon historical data. Quad-X will give us the data that once it's sufficient, we can make that change, but it's hard to predict. And I can only use past companies in terms of that timeline to kind of give you a range of an answer.

but it's becoming more and more sophisticated for us and we'll know when we know over the next couple quarters. Yeah I understand and once that happens we'll just be basically like you know you have a history of getting paid on you know X percent of your submission so you're able to record that you know fraction as revenue or something like that. That is correct so when the key determinant of when the service is delivered is when our lab submits the report to the referring physician.

That'll be the point of recognition. It is now the point of recognition, but there's one other consideration at that point, we have to take no account, is what is the likelihood of getting paid at the billed amount? And that's the unpredictable piece. So going forward with reimbursement, fully matured, where the predicted value of payment is pretty much short, the recognition will be at the point of delivery of the test from our lab to the referring physician. And we'll know based upon carriers.

United and Aetna and what we're getting paid by those different entities. And we'll develop the statistics by those entities to be able to record the revenue that we bill that we're submitted a claim for and recognize it at that point of delivery.

Okay, got it. And then just in terms of the lab operations, can you talk about the kind of gross margins at the current volumes? I mean, I know you're not getting paid on all the tests, but let's say that you were getting paid on most of them, or able to record the revenue, I guess you should say, on most of them. What would that gross margin look like currently? Our processing costs through the lab are about $120,000.

The coastline is around $60.

and the remaining balance of overhead probably is $200 rounded to the cost of revenue. We think that there's opportunity in the processing costs to bring them down as volume increases. Some of that will be through equipment efficiency and new equipment at higher volume efficiencies and some of it will just be the speed of which it moves through the facility as well as the cost of the lab supplies will go down.

margin improvements but generally thinking about it is that $200 per test you have a $2,000 billable test you're talking about a 90% margin obviously it'll take us some time to to get there that's probably how it plays itself out

Okay, got it. Thank you. The next question comes from Mark Masero with CTIG. Please go ahead. Good morning, Mark. Hey, good morning, Dennis. Good morning, Leeshaun. Congrats for another strong sequential volume quarter. You know, we're in the summer here, and I just wanted to ask about potential impacts related to seasonality. Were there any large events in Q2 that occurred that you think may not occur again in Q3 that would put your sequential volume growth trajectory at risk?

Let me, I'm glad you asked about that. Let's dive into that a little bit further. So the straight answer to your question is no. That as we sort of were hinting at earlier and we'll reiterate, that growth has been strong both in the organic, you know, direct physician referral side as well as the testing event. And the testing event volume is not just sort of individual events. Testing event volume is, you know, some of them are smaller. Some of them are, you know, hundreds of patients. Some of them are dozens of patients. So it's just another channel. And it's another channel that, you know, will we have identical growth in that compared to the other, you know, quarter to quarter? Maybe not. But it's not like it's so bulky and choppy in one that we would expect it to.

to mask sort of the sluggishness or slowing down on the other side. That said, I do want to sort of, I'm glad you mentioned this because I wanted to mention a little bit more about the increase in productivity, right? So we have, as I mentioned, we did freeze our sales team, the overall team at 38, 39.

and we've kept it there. And this growth has been driven by what we expected to happen, which is that with more tenure, we would have increased productivity, and productivity is about double this year in terms of the number of tests per seller per week. And we have a whole variety of initiatives and various sort of structured data-driven processes that we expect to.

So, you know, given the encouraging news from, you know, on the revenue cycle management side, you know, I think there's a good prospect that if we start seeing...

higher ASP per test collections that we might be in a position where we could say well we'll release that cap on the number of sellers and increase the number of sellers to accommodate potential plateauing of the productivity. But if we don't increase the number of sellers there'll be some point at which we'll plateau and we won't necessarily be able to continue to drive this kind of quarter-on-quarter growth without increasing the number.

of sellers and we won't do that until we have a little bit more attraction on the payment side. Hopefully that makes sense. A little bit of an off-comment there. Yeah, yep, yeah, still early days. So yeah, so my next question, now that the claim submission and adjudication pause.

is over and it sounds like you witnessed really strong trends in July . I'm curious if we could start to see the average realized prices trend back up almost to like the Q1 levels.

where you are in over $200 per test on revenue per test, or realized revenue per test. So I'm just trying to ask if you expect the sort of the billing and collections to manifest itself in terms of realizing price, and seeing that flow into revenue in Q3.

Yes, we believe that to be true, particularly since we're seeing the number of cases where

that are being adjudicated out of the code. That's why I gave some of those statistics. And the amount of the adjudication that results in an allowed amount is almost 40%, and we expect that to continue to grow with on-axes involvement.

and that translates into collections, then I think that number not only gets to the first quarter, but starts to exceed it on an accelerating basis quarter by quarter going forward.

Excellent. Last one for me real quick. As I think about these clinical utility studies, I think in the past you said you expect to complete them by the end of this calendar year. Is that still on track? And you know you provided an update on numbers. I think it's somewhere in the 200 range.

How much, how many more are you expecting to enroll and how long will that enrollment go on for? Yeah, thanks for giving me an opportunity to clarify that. So, clearly some of these studies, you know, enroll on an ongoing basis and you get a certain number and you can publish them. It's not like, you know, that has a...

pre-specified endpoints and things like that, like you would need to know what are these studies. So what I should have been clear about is that the CLU study, which is enrolled 206 patients, will be targeted to enroll up to 500 patients, and we expect to complete that enrollment by the end of the year.

the Lucid Registry is open-ended. It'll continue to enroll as long as we find it useful, both from a clinical utility point of view, but the Lucid Registry actually has a clinical validity component to it as well because we're actually diving further down into the patient's journey to get endoscopy data on those that are positive. So it serves a whole variety of other purposes as well. What I was trying to, and hopefully maybe wasn't clear about it, is that our goal...

with regard to our first submission of a clinical utility study was to get to a total of 300 patients by the mid-summer. We've exceeded that at 500. So we are gonna take the patients that we have enrolled to date, and we're analyzing that data and expect to submit that as a standalone manuscript, one for clue, one for registry by the end of this month. But they'll both continue to enroll, and we'll look to submit additional data as we get larger numbers and tweak the analyses accordingly. I assume you've seen that.

in other companies as well with regard to just sort of multiple increasing volume of the amount of clinical utility. So the amount of patients under that, we wanted to get this kind of 400 number because that's you need enough positives to demonstrate that a positive will get an endoscopy. And so we've definitely reached that number where that's going to be a meaningful data.

basically this is our first set of tools to engage payers on clinical utility and we intend to do that and we continue to evolve that with additional amounts and additional dimensions of clinical utility to engage them even further if there's any pushback at this first level of data. More is better. That's from monitoring some other companies as well.

But there have definitely been some repeat customers where the enthusiasm for an event and the positive feedback has led to us going back and just testing more people. Extremely high patient satisfaction. Great. Well, thanks for answering my questions, and I wish you guys good luck. Thank you. Yeah. Thanks, Ben. This concludes our question-and-answer session. I would like to turn the conference back over to Dr. Akhilaf Rennie, closing remarks. Great. So, thank you all for your attention. I'd like to thank the questions. We're great, and we look forward to continuing to update you on our progress through press releases and follow-up calls. Feel free to contact us through mic at MEP at patmed.com.